Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment – real world outcomes

BACKGROUND: The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9 months of erenumab treatment in a cohort of patients with difficult-to-control chronic migrai...

Descripción completa

Detalles Bibliográficos
Autores principales: Talbot, J., Stuckey, R., Crawford, L., Weatherby, S., Mullin, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797151/
https://www.ncbi.nlm.nih.gov/pubmed/33421995
http://dx.doi.org/10.1186/s10194-020-01214-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797151/
https://www.ncbi.nlm.nih.gov/pubmed/33421995
http://dx.doi.org/10.1186/s10194-020-01214-2

Ejemplares similares